COMPARISON · REVIEW DRAFT
Semaglutide and tirzepatide: reference comparison
Research reference only. Source-reported examples and schedules are not dosing recommendations from MGMT Research. They do not establish safety or suitability. Prescribed medication decisions belong with a licensed clinician and the current product label.
Reference notes
These compounds use different receptor targets and dose scales. A milligram amount for one is not an equivalent amount of the other.
The calculation remains concentration = vial mass ÷ liquid volume, then target volume = target mass ÷ concentration. The source values below are contextual examples, not treatment choices.
| Measure | Semaglutide | Tirzepatide |
|---|---|---|
| Targets | GLP-1 | GLP-1 / GIP |
| Vials, mg | 2.5 / 5 / 10 | 5 / 10 / 15 |
| Dose range | 250 mcg–2.4 mg | 2.5–15 mg |
| Half-life | ~7 days | ~5 days |
Source & content review 2 notes
This is an original, concise draft. Full information and numerical parity with the source is not yet established.
Open source reference ↗- Source numeric coverage is partial: selected reference values are preserved; all additional source tables and examples still require reconciliation before claiming full fidelity.
- Source range is not a complete current product-label summary. See Wegovy review issue.
Captured source values
{
"numericalFacts": []
}